Using stellate ganglion block to treat advanced Parkinson's disease
Stellate Ganglion Block in Patients With Advanced Primary Parkinson's Disease: a Small, Open, Randomized Controlled Clinical Study
This study is testing whether a special nerve block can help people with advanced Parkinson's disease feel better by improving their movement and other symptoms.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 38 (estimated) |
| Ages | 40 Years to 85 Years |
| Sex | All |
| Sponsor | Zhujiang Hospital Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06112392 on ClinicalTrials.gov |
What this trial studies
This clinical study investigates the use of stellate ganglion block as a treatment for patients with intermediate and advanced Parkinson's disease. It aims to determine whether this intervention can effectively improve both motor and non-motor symptoms associated with the disease. The study will be conducted as an open, randomized controlled trial with a small sample size, focusing on patients who meet specific diagnostic criteria for Parkinson's disease. The research is motivated by the limitations of current drug therapies, particularly in advanced stages of the disease.
Who should consider this trial
Good fit: Ideal candidates for this study are patients aged 40-85 with a confirmed diagnosis of Parkinson's disease who are experiencing intermediate to advanced symptoms.
Not a fit: Patients with Parkinson's superposition syndrome or those allergic to local anesthetics may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly enhance the quality of life for patients suffering from advanced Parkinson's disease.
How similar studies have performed: There are currently no reports on the application of stellate ganglion block for Parkinson's disease, making this approach novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with Parkinson's disease who met the diagnostic criteria for MDS as "probable PD" or" confirmed PD" in 2016 Inclusion criteria: 1. Age 40-85; 2. Patients with Parkinson's disease who met the diagnostic criteria of MDS as "probable PD" or" confirmed PD" in 2016; 3. The patient or his/her legal guardian agrees to participate in the study and signs the informed consent; 4. Hoehn-yahr (H\&Y) 2.5 \~ 5; Exclusion Criteria: * 1. Allergic to local anesthetic drugs; 2. Unable to cooperate with motor or non-motor function monitoring; 3. Patients with Parkinson's superposition syndrome, such as cortical basal ganglia degeneration, lewy body dementia, multisystem atrophy and progressive supranuclear palsy, were excluded; Patients with secondary Parkinson's disease, such as vascular Parkinson's disease, drug toxicity or traumatic Parkinson's disease; 4. Refuse to sign the consent form.
Where this trial is running
Guangzhou, Guangdong
- Zhujiang Hospiatal — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Principal investigator: Xiaoya Gao, doctor — Southern Medical University, China
- Study coordinator: Xiaoya Gao, doctor
- Email: gaoxy23@126.com
- Phone: 86-18680282869
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.